Diffuse myocardial fibrosis resulting from the excessive deposition of collagen fibres through
the entire myocardium is encountered in a number of chronic cardiac diseases. This lesion …

Background Chronic heart failure (HF) is a growing global health challenge. People with HF
experience substantial burden that includes low exercise tolerance, poor health‐related …

Background Drug combinations rather than increasing doses of one drug can achieve
greater efficacy and lower risks. Thus, as an alternative to high-intensity statin monotherapy …

Background: Poor health-related quality of life (HRQL) is common in heart failure (HF), but
there are few data on HRQL in HF and the association between HRQL and mortality outside …

The selection of appropriate outcomes is crucial when designing clinical trials in order to
compare the effects of different interventions directly. For the findings to influence policy and …

Background: Subclinical inflammation is associated with an increased risk of heart failure
and with adverse prognosis in patients with established heart failure. Yet, treatments …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

This publication, commissioned by the ACC/AHA, is the product of a novel collaboration
between the ACC and AHA, the US Food and Drug Administration (FDA), and the …

Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Background Several hundred core outcome set (COS) projects have been systematically
identified to date which, if adopted, ensure that researchers measure and report those …